MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

Search

BioMarin Pharmaceutical Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

62.84 0.59

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

61.49

Max

62.77

Pagrindiniai rodikliai

By Trading Economics

Pajamos

19M

125M

Pardavimai

1.6M

747M

P/E

Sektoriaus vid.

26.539

57.333

Pelnas, tenkantis vienai akcijai

0.92

Pelno marža

16.719

Darbuotojai

3,040

EBITDA

39M

195M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+57.54% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-01

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-729M

11B

Ankstesnė atidarymo kaina

62.25

Ankstesnė uždarymo kaina

62.84

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

BioMarin Pharmaceutical Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-06-10 17:41; UTC

Pagrindinės rinkos jėgos

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

2024-08-21 11:30; UTC

Svarbiausios naujienos

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Akcijų palyginimas

Kainos pokytis

BioMarin Pharmaceutical Inc Prognozė

Kainos tikslas

By TipRanks

57.54% į viršų

12 mėnesių prognozė

Vidutinis 97.58 USD  57.54%

Aukščiausias 126 USD

Žemiausias 70 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines BioMarin Pharmaceutical Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

21 ratings

16

Pirkti

5

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

61.5 / 63.39Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.